Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Mologen AG. (9/26/16). "Press Release: Capital Increase through Rights Issue and Issuance of a Convertible Bond [Not for USA, Australia, Canada or Japan, et al.]".

Organisations Organisation Mologen AG
  Group Mologen (Group)
  Organisation 2 TowerCrest LLC (CN)
Products Product lefitolimod (MGN1703)
  Product 2 EnanDIM® technology
Index terms Index term Mologen–SEVERAL: investment, 201609–201610 capital increase €13.6m 11.316m common shares at €1.2/share (raising no. of existing shares by up to 50%)
  Index term 2 Mologen–Global Derivative Trading: credit, 201609– convertible bond with total nominal value of €2.54m by largest investor GDT
Persons Person Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
  Person 2 Nickolaus, Claudia (Mologen 201407– Head Investor Relations)
     


   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Mologen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top